NWCJvdD has served in a consulting/advisory role for AbbVie, Adaptive Biotechnologies, Amgen, Bayer, BMS, Celgene, Janssen, Kite Pharma, Merck, Novartis, Pfizer, Roche, Servier, and Takeda; and has received research funding from Amgen, BMS, Celgene, Cellectis, Janssen, and Novartis. NB has served in a consulting/advisory role for Amgen, Celgene, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi, and Takeda; received honoraria from AbbVie, Amgen, Celgene, Genentech/Roche, GSK, Janssen, Karyopharm Therapeutics, Sanofi, and Takeda; and has received research funding from Celgene, Janssen, and Pfizer. LJC has served in a consulting role for AbbVie, Amgen, BMS, Pfizer, and Sanofi; has received grants or contracts from AbbVie, Amgen, and BMS; and has received research funding from Janssen. M-VM reports honoraria from and membership on a board of directors and/or advisory committee for Amgen, BMS/Celgene, GSK, Janssen-Cilag, Pfizer, Sanofi, and Takeda; is a speakers bureau member for Janssen-Cilag; and is a board of directors and/or advisory committee member for Oncopeptides. AKN has served on advisory boards and received honoraria from Adaptive Biotechnologies, Amgen, BeyondSpring, BMS, Cellectar Biosciences, GSK, Janssen, Karyopharm Therapeutics, Oncopeptides, ONK Therapeutics, Pfizer, Sanofi, Secura Bio, and Takeda; received grant/research support (to university) from Aduro Biotech, Amgen, Arch Oncology, BMS, Cellectar Biosciences, Cellectis, Genentech, GSK, Janssen, Karyopharm Therapeutics, Kite Pharma, Merck, Pfizer, and Takeda; and received grant/research support for investigator-initiated studies from Amgen, GSK, Janssen, Merck, and Takeda. AP has received honoraria or consultancy from AbbVie, Amgen, BMS, Janssen, Pfizer, Sanofi, and Takeda. ALG has served in a consulting or advisory role for Abbvie, Amgen, Bristol Myers Squibb/Celgene, CDR-Life, GlaxoSmithKline, Gracell, Janssen Oncology, Novartis, Regeneron, and Smart Immune; received travel, accommodations, or expenses from Janssen; has a patent in the field of CAR-T cell therapy; and received research funding from Crispr Therapeutics, Janssen Oncology, Novartis, and Tmunity Therapeutics, Inc. PT, KQ, CU, KC, and MD are employees of Janssen. SZU has served in a consulting/advisory role for AbbVie, Amgen, BMS/Celgene, Celgene, Genentech, Genentech/Roche, Gilead Sciences, GSK, Janssen Oncology, K36 Therapeutics, Karyopharm Therapeutics, and Takeda; and has received research funding from AbbVie, Amgen, Array BioPharma, BMS, Celgene, Gilead, GSK, Janssen Oncology, Merck, Pharmacyclics, Sanofi, Seagen, and SkylineDx.
Ethics approval and consent to participateThe MajesTEC-1 study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each of the study sites (a full list of which has been published previously [16]). All patients provided written informed consent.
留言 (0)